Company Overview of Novartis Pharma AG
Novartis Pharma AG provides treatments for Alzheimer’s disease, Parkinson’s disease, Attention-Deficit/Hyperactivity Disorder, epilepsy, schizophrenia, and migraine. It is also developing a treatment for type 2 diabetes; drugs therapies that improve insulin action to increase glucose disposal in the muscle, to limit its production in the liver, and to improve the kinetics of insulin secretion; and oral and physiological approach to enhancing glucagon like peptide-1 activity, which acts to stimulate insulin secretion and inhibit glucagon production. The company is based in Basel, Switzerland. Novartis Pharma AG operates as a subsidiary of Novartis AG.
41 61 324 11 11
41 61 324 80 01
Key Executives for Novartis Pharma AG
President of HBA Europe and Head of New Marketing Initiatives
Global Head of Respiratory and Dermatology
Compensation as of Fiscal Year 2014.
Novartis Pharma AG Key Developments
Genmab Reaches Deal to Transfer Ofatumumab Collaboration with GSK to Novartis
Nov 3 14
Genmab A/S has entered into an agreement with GlaxoSmithKline and Novartis Pharma AG to transfer the ofatumumab collaboration with GSK to Novartis. The transfer of the collaboration follows an April 2014 announcement in which Novartis, as part of a definitive agreement reached with GSK, agreed to acquire GSK's oncology products including ofatumumab. The transfer of the collaboration will only become effective upon closing of the GSK/Novartis Transaction, which is currently expected in the first half of 2015. Upon transfer, Novartis would develop and commercialize ofatumumab in oncology indications and GSK would continue to develop and commercialize ofatumumab for autoimmune indications. The parties have also agreed that Genmab would not be required to pay existing funding liabilities (approximately GBP 19 million or DKK 180 million)or to fund research and development costs for ofatumumab beyond December 31, 2014. In aggregate, this could reduce Genmab's funding commitment by up to GBP 60 million or DKK 570 million.
Novartis Pharma AG Presents at BIO-Europe 2014, Nov-03-2014 03:15 PM
Oct 31 14
Novartis Pharma AG Presents at BIO-Europe 2014, Nov-03-2014 03:15 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany. Speakers: Markus Kalousek, Global BD&L, S&E Franchise Head, Integrated Hospital Care.
Novartis Pharma AG Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014
Jul 31 14
Novartis Pharma AG Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland. Presentation Date & Speakers: Oct-01-2014, Corinne Savill, Head BD&L. Sep-30-2014, Anthony Rosenberg, Head of BD and Licensing, Guy Greiveldinger, Director BD&L and M&A, Rao Movva, Novartis Distinguished Scientist, Executive Director.
Similar Private Companies By Industry
Recent Private Companies Transactions